Can a bispecific antibody tame two autoimmune blood disorders?
NCT ID NCT07738822
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial is testing an investigational drug called velinotamig in adults with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has relapsed or not responded to standard treatments. Velinotamig is an engineered bispecific antibody designed to target BCMA and CD3, potentially modulating the immune system. The study aims to evaluate the safety and tolerability of the drug, given as a subcutaneous injection, in a small group of participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- velinotamig (also known as CLN-803, GR1803), an engineered bispecific antibody targeting BCMA and CD3
- What this could lead to
- If successful, this could lead to a new treatment option for people with immune thrombocytopenia or warm autoimmune hemolytic anemia who have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not prove safe or effective. Possible side effects include immune-related reactions and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cullinan Investigative Site
Webster, Texas, 77598, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an RNA 'Message' reprogram the immune system to stop autoimmune blood disorders?
- Can a gut bacteria transplant help when steroids fail for a bleeding disorder?
- Experimental drug ANX005 targets blood cell destruction in autoimmune anemia
- Will a new drug form work the same? study tests two versions of SKI-O-703
- New pill could help patients with rare blood disorder
- New drug mimics IVIg to fight low platelet disorder